Senti Biosciences, Inc., a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform. The company is building a synthetic biology platform that may enable it to program next-generation cell and gene therapies with what the company refer to as Gene Circuits. These novel and proprietary Gene Circuits are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. Senti Bio aims to design Gene Circuits to improve the intelligence of cell and gene therapies in order to enhance their therapeutic effectiveness, precision, and durability against a broad range of diseases that conventional medicines do not readily address. Senti Bio's synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuit technologies, to target particularly challenging liquid and solid tumor oncology indications. The company's lead product candidate is SENTI-202 for the treatment of CD33 and/or FLT3 expressing hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Additionally, the company's SENTI-401 program is being designed for the treatment of colorectal cancer (CRC) and other CEA-positive cancers. Senti Bio has also demonstrated in preclinical studies the potential breadth of Gene Circuits in other modalities, including T cells, adeno-associated viruses (AAVs) and induced pluripotent stem cells (iPSCs), and diseases outside of oncology. Senti Bio has executed partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.